Regenxbio
RGNX
108 hedge funds and large institutions have $718M invested in Regenxbio in 2017 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 10 closing their positions.
190% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 10
107% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $6.3M
21% more funds holding
Funds holding: 89 → 108 (+19)
2% more capital invested
Capital invested by funds: $704M → $718M (+$13.6M)
0.14% more ownership
Funds ownership: 69.15% → 69.29% (+0.14%)
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$23.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$11.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.41M |
| 4 |
DM
Deerfield Management
New York
|
+$7.72M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$23.8M |
| 2 |
BlackRock
New York
|
-$21.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$13.7M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
-$12.5M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$7.3M |
RGNX Hedge Fund Activity: Q4 2017 in Review
108 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2017, worth a combined $718M — up 1.9% from $704M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RGNX positions and 10 closed out — a net gain of 19 holders — while 30 added to existing stakes and 34 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $23.2M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $23.8M sold.
- 108 institutional investors held Regenxbio (RGNX) as of Q4 2017, up from 89 in Q3 2017.
- Funds reported $718M of Regenxbio stock for Q4 2017, up 1.9% quarter-over-quarter.
- 29 funds opened new Regenxbio positions in Q4 2017 and 10 closed out, a net change of +19 holders.
- The largest Regenxbio buyer in Q4 2017 was PFM Health Sciences, an estimated $23.2M added.
- The largest Regenxbio seller in Q4 2017 was Bain Capital Public Equity Management, an estimated $23.8M sold.
Based on aggregated 13F filings for Q4 2017.